EUVIMEDEUVIMED entdecken
Crossref

Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

N. Ben Khaled, B. Mörtl, D. Beier, F. P. Reiter, D. Pawlowska-Phelan, A. Teufel, D. Rössler, D. Schwade, A. Philipp, I. Kubisch, U. Ehmer, A. Geier und 5 weitere

Zeitschrift für Gastroenterologie · 01.05.2024 · 62 (05) · e449-e450

DOI: 10.1055/s-0044-1785616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2024. Verfasst von N. Ben Khaled und 16 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Einleitung The treatment of hepatocellular carcinoma (HCC) is undergoing a historic transformation with the availability of several new systemic therapies [ 1 ]. The impact of this changing landscape on patient outcomes has not yet been studied in a German cohort in a nationwide, real-world setting. Material und Methodik This observational, retrospective study is based on a claims data base including anonymized, longitudinal data of around 8.8 million persons (InGef database). We assessed the implementation and impact of systemic therapies for patients with HCC in nationwide clinical routine in three parts: First, we describe patient characteristics, drug treatments, and associated costs in a large, representative cohort of patients with HCC between 2015 and 2020. Second, we examine the association between drug availability and outcomes comparing survival of HCC patients by date of initiation of systemic therapy. Survival in an era with only sorafenib (period A, 01/2015-08/2018) and after approval of lenvatinib and other systemic treatments (period B, 08/2018-12/2020) was analyzed. Third, we explore the impact of treatment sequencing based on lenvatinib or sorafenib in the first line setting after the approval of lenvatinib in 2018. Ergebnisse We identified 2876 individuals with HCC in the study period. The proportion of patients receiving systemic therapy increased significantly over time, from 11.8% in 2015 to 15.1% in 2020 (p

Zitieren

APA

Khaled, N. B., Mörtl, B., Beier, D., Reiter, F. P., Pawlowska-Phelan, D., Teufel, A., Rössler, D., Schwade, D., Philipp, A., Kubisch, I., Ehmer, U., Geier, A., Lange, C. M., Mayerle, J., Berger, K., Toni, E. N. D., & Munker, S. (2024). Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study. Zeitschrift für Gastroenterologie, 62(05), e449-e450. https://doi.org/10.1055/s-0044-1785616

Vancouver

Khaled NB, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, et al. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study. Zeitschrift für Gastroenterologie. 2024;62(05):e449-e450. doi:10.1055/s-0044-1785616

BibTeX
@article{Khaled2024,
  author = {Khaled, N. Ben and Mörtl, B. and Beier, D. and Reiter, F. P. and Pawlowska-Phelan, D. and Teufel, A. and Rössler, D. and Schwade, D. and Philipp, A. and Kubisch, I. and Ehmer, U. and Geier, A. and Lange, C. M. and Mayerle, J. and Berger, K. and Toni, E. N. De and Munker, S.},
  title = {Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {05},
  pages = {e449--e450},
  doi = {10.1055/s-0044-1785616}
}
Kostenlos starten →